0001104659-20-132155.txt : 20201203
0001104659-20-132155.hdr.sgml : 20201203
20201203214139
ACCESSION NUMBER: 0001104659-20-132155
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201201
FILED AS OF DATE: 20201203
DATE AS OF CHANGE: 20201203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Alkon Daniel L.
CENTRAL INDEX KEY: 0001686138
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38045
FILM NUMBER: 201368481
MAIL ADDRESS:
STREET 1: C/O NEUROTROPE, INE.
STREET 2: 205 EAST 42ND STREET - 20TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neurotrope, Inc.
CENTRAL INDEX KEY: 0001513856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463522381
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: (973) 242-0005
MAIL ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: BlueFlash Communications, Inc.
DATE OF NAME CHANGE: 20110223
4
1
tm2037705d7_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2020-12-01
0
0001513856
Neurotrope, Inc.
NTRP
0001686138
Alkon Daniel L.
C/O NEUROTROPE, INC.
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK
NY
10036
0
1
0
0
See Remarks
Common Stock
2020-12-01
4
D
0
29688
D
0
D
Stock Option (right to buy)
56.00
2020-12-01
4
D
0
5469
D
Common Stock
5469
0
D
Stock Option (right to buy)
10.56
2020-12-01
4
D
0
124274
D
Common Stock
124274
0
D
Stock Option (right to buy)
19.62
2020-12-01
4
D
0
167000
D
Common Stock
167000
0
D
Stock Option (right to buy)
3.93
2020-12-01
4
D
0
150000
D
Common Stock
150000
0
D
Stock Option (right to buy)
0.972
2020-12-01
4
D
0
40000
D
Common Stock
40000
0
D
Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
President, Chief Scientific Officer
/s/ Robert Weinstein, Attorney-in-Fact
2020-12-03